Neoduplamox (Amoxicillin, Clavulanic Acid)

Amoxicillin disrupts bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which prevents the formation of essential peptidoglycan cross‑links. Clavulanic acid inhibits β‑lactamase enzymes that many resistant bacteria produce, protecting amoxicillin from enzymatic breakdown. This dual mechanism broadens the antimicrobial spectrum and results in bactericidal activity against both Gram‑positive and Gram‑negative organisms.

The appropriate dose of Neoduplamox is individualized by the prescribing healthcare professional based on the type and severity of infection, patient age, weight, renal and hepatic function, and any concomitant medications. Dosage regimens are not standardized in public information and should follow the prescriber’s instructions and local clinical guidelines.

Amoxicillin/clavulanic acid is classified as a pregnancy category B medication in many regions, indicating that animal studies have not shown risk but adequate human studies are lacking. It may be used during pregnancy only if clearly needed. Limited data suggest it is excreted in breast milk in small amounts; breastfeeding decisions should be made in consultation with a healthcare provider.

To request Neoduplamox, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Plain amoxicillin is effective against many susceptible bacteria but can be inactivated by β‑lactamase enzymes produced by resistant strains. Adding clavulanic acid in Neoduplamox extends coverage to β‑lactamase‑producing organisms, making it useful for infections where resistance is a concern. However, the combination may have a higher incidence of gastrointestinal side effects compared with amoxicillin alone.

Neoduplamox tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Neoduplamox is taken orally, usually as a tablet, with a full glass of water. It can be taken with or without food, although taking it with food may reduce gastrointestinal upset. The exact dosing schedule—such as frequency and duration—must be prescribed by a qualified healthcare professional.

Serious adverse reactions include anaphylaxis or severe allergic responses, Stevens‑Johnson syndrome or toxic epidermal necrolysis, Clostridioides difficile‑associated colitis, significant liver injury, neutropenia, and rare neurologic events such as seizures. Patients should seek immediate medical attention if they experience symptoms like difficulty breathing, rash with blistering, persistent diarrhea, jaundice, or unexplained bruising.

Neoduplamox is contraindicated in individuals with a known hypersensitivity to amoxicillin, clavulanic acid, or any other β‑lactam antibiotics. Patients with a history of severe allergic reactions to penicillins should avoid this medication. Caution is also advised for those with severe hepatic impairment, and the drug should be used only under medical supervision in such cases.